Latest News in the pharma Industry

Research & Development

Bausch + Lomb and Nicox announce FDA Acceptance of NDA for novel glaucoma candidate

Bausch + Lomb and Nicox announce FDA Acceptance of NDA for novel glaucoma candidate

22 Sep 2015

If approved, Vesneo will be the first nitric oxide donating prostaglandin receptor agonist available for patients with open angle glaucoma or ocular hypertension.

Read more 
Targeting DNA — protein-based sensor could detect viral infection or kill cancer cells

Targeting DNA — protein-based sensor could detect viral infection or kill cancer cells

21 Sep 2015

MIT biological engineers have developed a modular system of proteins that can detect a particular DNA sequence in a cell and then trigger a specific response, such as cell death.

Read more 
Regeneron announces agreement with BARDA for the development of new antibody treatment for Ebola

Regeneron announces agreement with BARDA for the development of new antibody treatment for Ebola

21 Sep 2015

HHS will provide initial funding of approximately $17 million to support preclinical development and antibody manufacturing. This initial funding is designed to support an Investigational New Drug application with the FDA.

Read more 
Jardiance is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

Jardiance is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

18 Sep 2015

Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company's Jardiance (empagliflozin) significantly reduced the risk of the combined endpoint of cardiovascular (CV) death, non-fatal heart attack or non-fatal stroke by 14% when added to standard of...

Read more 
Victoza (liraglutide) provides significantly greater HbA1c reduction than lixisenatide in new clinical trial

Victoza (liraglutide) provides significantly greater HbA1c reduction than lixisenatide in new clinical trial

17 Sep 2015

Findings from a head-to-head trial comparing Victoza (liraglutide) and lixisenatide, both in combination with metformin, demonstrated a significantly greater reduction in HbA1c of -1.83% for liraglutide vs -1.21% for lixisenatide in adults with type 2 ...

Read more 
CEVEC and Généthon sign a collaboration agreement to develop lentiviral vector packaging cell lines based on CEVEC’s proprietary CAP GT technology

CEVEC and Généthon sign a collaboration agreement to develop lentiviral vector packaging cell lines based on CEVEC’s proprietary CAP GT technology

17 Sep 2015

Agreement enables fully scalable, industrial lentivirus vector production

Read more 
Merck's omarigliptin achieved similar A1C reductions to Januvia in patients with type 2 diabetes inadequately controlled on Metformin monotherapy

Merck's omarigliptin achieved similar A1C reductions to Januvia in patients with type 2 diabetes inadequately controlled on Metformin monotherapy

17 Sep 2015

Omarigliptin was found to be non-inferior to Merck’s once-daily DPP-4 inhibitor, Januvia (sitagliptin), at reducing patients’ A1C levels from baseline, with similar A1C reductions achieved in both groups.

Read more 
Using proteomics to understand how genetic mutations rewire cancer cells

Using proteomics to understand how genetic mutations rewire cancer cells

17 Sep 2015

Scientific publications highlight studies using data from Thermo Scientific Orbitrap mass spectrometry and next-generation sequencing to discover how cancer attacks the protein networks controlling human cells

Read more 
BMS’s Opdivo (nivolumab) receives breakthrough therapy designation from FDA for advanced renal cell carcinoma

BMS’s Opdivo (nivolumab) receives breakthrough therapy designation from FDA for advanced renal cell carcinoma

16 Sep 2015

This is the fourth Breakthrough Therapy Designation granted for Opdivo by the FDA

Read more 
Opsonix launches with $8 million Series A to develop pathogen-extracting therapy for sepsis and other blood-borne infectious diseases

Opsonix launches with $8 million Series A to develop pathogen-extracting therapy for sepsis and other blood-borne infectious diseases

8 Oct 2015

The company’s sepsis therapy has the potential to be used not only in combination with existing antibiotics, but also to treat patients when conventional therapeutic options are not available.

Read more 
Navitor Pharmaceuticals’ scientific founder makes landmark discovery of the molecular sensor for the amino acid leucine

Navitor Pharmaceuticals’ scientific founder makes landmark discovery of the molecular sensor for the amino acid leucine

8 Oct 2015

Finding the long sought-after mediator of mTORC1 activation by leucine opens up opportunities for creating new medicines for metabolic, musculoskeletal, autoimmune and other age-related diseases.

Read more 
FDA expands use of Novartis drug Promacta to include treatment of children ages 1 and older with chronic immune thrombocytopenia

FDA expands use of Novartis drug Promacta to include treatment of children ages 1 and older with chronic immune thrombocytopenia

26 Aug 2015

Read more